SLC25A13

Electrogenic aspartate/glutamate antiporter SLC25A13, mitochondrial · Q9UJS0 · SLC25A13 on Sugi Atlas →

0 patent compounds predicted against SLC25A13, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to SLC25A13 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Glutamate for Metabolic Intervention in Coronary Surgery PHASE3COMPLETED
Sedation of Ventilated Traumatic Brain Injury Patients With Midazolam Alone Versus Combination With Dexmedetomidine or Magnesium Sulfate; Monitored by Ultrasonograghic Optic Nerve Sheath Diameter PHASE3UNKNOWN
Applying Proton Pump Inhibitor to Prevent and Treat Acute Fluctuating Hearing Loss in Patients With SLC26A4 Mutation PHASE2/PHASE3UNKNOWN
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia PHASE1/PHASE2RECRUITING
Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis PHASE2UNKNOWN
Mitochondrial Dysfunction in the Pathophysiology and Treatment of Bipolar Disorder PHASE2WITHDRAWN
DAAOI-1 Treatment for Treatment-resistant Schizophrenia PHASE2COMPLETED
D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia PHASE2COMPLETED
A Phase I/II Open-label Safety and Efficacy Study of LNP.UCD.ABE in Patients With Urea Cycle Disorders. PHASE1/PHASE2NOT_YET_RECRUITING
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders PHASE2COMPLETED
Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients PHASE2COMPLETED
A Glutamate Transporter GLT1, in the Treatment of Bipolar Disorder PHASE2WITHDRAWN
A Study of Oxidative Pathways in MS Fatigue PHASE2COMPLETED
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia PHASE1COMPLETED
Excitatory Amino Acids and Activated Microglia After Traumatic Brain Injury: a (R)-[11C]PK11195 PET Study PHASE1UNKNOWN
SLC13A5 Deficiency Natural History Study - United States Only nanENROLLING_BY_INVITATION
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy nanCOMPLETED
Multi-omics Study in Citrin Deficiency nanACTIVE_NOT_RECRUITING
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts nanCOMPLETED
High Dose Omega-3 Fatty Acids in the Treatment of Sport Related Concussions nanCOMPLETED
Triheptanoin (UX007) to Treat Citrate Transporter Deficiency nanNO_LONGER_AVAILABLE
Oxalate and Citrate in Humans - Response to Citrate nanRECRUITING
Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy nanUNKNOWN
Expression of SLC25A48 in Chronic Obstructive Pulmonary Disease nanNOT_YET_RECRUITING
sCD163 in ALS Patients nanCOMPLETED
Potential Synergistic Effect of Combined Blood Flow Restriction Training and Betaine Supplementation on Skeletal Muscle nanCOMPLETED
GABA/Glutamate Balance in Temporal Lobe Epilepsy With and Without Major Depression nanCOMPLETED
Core Stability Exercises and Hereditary Ataxia nanCOMPLETED
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease nanCOMPLETED
Clinical and Laboratory Study of Methylmalonic Acidemia nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a SLC25A13 binder may also engage these)

ProteinNameSimilarity
F1LZW6 1.000 F1LZW6 →
Q9QXX4 1.000 Q9QXX4 →
Q8HXW2 1.000 Q8HXW2 →
Q8BH59 1.000 Q8BH59 →
Q5RBC8 1.000 Q5RBC8 →
O75746 0.999 O75746 →
F1LX07 0.993 F1LX07 →
Q9FLS8 0.985 Q9FLS8 →
Q9VA73 0.982 Q9VA73 →
Q0V7M4 0.982 Q0V7M4 →
Q8K3P6 0.982 Q8K3P6 →
A2CEQ0 0.982 A2CEQ0 →
Q5XH95 0.980 Q5XH95 →
Q6NYZ6 0.979 Q6NYZ6 →
Q5XHA0 0.979 Q5XHA0 →
Q8BMD8 0.977 Q8BMD8 →
A2ASZ8 0.977 A2ASZ8 →
Q7ZYD5 0.976 Q7ZYD5 →
Q7T0U6 0.975 Q7T0U6 →
Q9BV35 0.975 Q9BV35 →
Q6NUK1 0.974 Q6NUK1 →
Q6GQS1 0.974 Q6GQS1 →
Q6KCM7 0.974 Q6KCM7 →
O18757 0.974 O18757 →
A5PJZ1 0.974 A5PJZ1 →
Q7ZY36 0.973 Q7ZY36 →
Q21153 0.973 Q21153 →
Q66L49 0.972 Q66L49 →
P79881 0.971 P79881 →
P51177 0.969 P51177 →